Allergy Therapeutics (AGY)

 

AGY Share PerformanceMore

52 week high33.00 18/09/17
52 week low17.25 26/09/16
52 week change 13.88 (75.51%)
4 week volume2,549,053 25/08/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Allergy Therapeutics gets approval for PQ Grass trial

Allergy Therapeutics has received approval for a phase II clinical trial of investigating the dosing of PQ Grass, an ultra-sho...

Approval for PQ Grass Phase II trial

RNS Number: 9660Q Allergy Therapeutics PLC 18 September 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Approval of clinical trial application for PQ Grass Phase II trial - Trial aimed at determining optimal dose of an MPL-adjuvanted, modified grass allergy vaccine - 18 September 2017 Allergy Therapeutics plc (AIM:AGY), the fully integra...

Allergy Therapeutics expands R&D and clinical team

Allergy Therapeutics has announced new senior appointments and expansion of the R&D and clinical team in line with th...

Expansion of Clinical Development and R&D teams

RNS Number: 2846Q Allergy Therapeutics PLC 11 September 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Expansion of Clinical Development and R&D teams - Key appointments reflect Group's commitment to EU and US strategy for product development - 11 September 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated special...

Allergy Therapeutics schedules FY results

Allergy Therapeutics, the fully integrated specialty pharmaceutical group specialising in allergy vaccines, will issue its preli...

Notice of Results

RNS Number: 9619N Allergy Therapeutics PLC 15 August 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Notice of Preliminary Results 15 August 2017 Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical group specialising in allergy vaccines, will issue its preliminary results for the year ended 30 June 2017 on Thursd...

Broker Forecast - finnCap issues a broker note on Allergy Therapeutics PLC

finnCap today reaffirms its buy investment rating on Allergy Therapeutics PLC (LON:AGY) and raised its price target to ...

Allergy Therapeutics ahead of forecasts

Allergy Therapeutics expects revenues for the year ended 30 June to be ahead of market forecasts at 64.1m (2016: 48.5m). A ...

Fundamental DataMore

EPS-2.29
Dividend yield0 %

Equity Research (AGY)

hardman & co
Allergy Therapeutics plc
19/07/2017
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in the EU only on a ‘Named...
hardman & co
Allergy Therapeutics plc
06/04/2017
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in EU only on a ‘Named Patient’...
Allergy Therapeutics plc
15/11/2016
InnovaDerma* (IDP.L) 107.5p £10.98m Strong news flow this week from the main market listed  UK developer of 'at-home' and clinically proven treatments for hair loss, hair care, self-...

Latest discussion posts More

  • Re: Screaming at us

    .....and those screams just got a lot louder, with Professor Tim H. guiding this one, they certainly appear to be taking a belt and braces approach this time. exuding ...
    18-Sep-2017
    Baffler
  • Screaming at us

    They are certainly exuding confidence with that announcement Tim doing the USA says it all for me Bring it on
    11-Sep-2017
    Baffler
  • Re: As good as it gets at this stage.

    it appears that finnCap have today reaffirms its buy investment rating on Allergy Therapeutics PLC (LON:AGY) and raised its price target to 46p (from 43p).This follows AGY ...
    18-Jul-2017
    d gaser

Users' HoldingsMore

Users who hold Allergy Therapeutics also hold..
LLOYDS GRP.27%
BP23%
NATIONAL GRID18%
BT GROUP17%
VODAFONE GRP.17%

Codes & Symbols

ISINGB00B02LCQ05
SymbolsAGY, LSE:AGY, AGY.L, AGY:LN, LON:AGY, XLON:AGY